Skip to main content

Durable Medical Equipment (DME) Additions to Preauthorization for Patients on Highmark’s System

October 22, 2021

To: DME providers

We will adopt many of Highmark’s preauthorization requirements for your patients as they gradually move onto Highmark’s system. Durable medical equipment (DME) is one area where requirements for preauthorization will be expanded from what we currently require.

Please review Highmark’s list of procedures/DME requiring authorization so you will be prepared to request authorization for patients who have moved onto Highmark’s system.

You will be able to use the NaviNet electronic portal for requesting preauthorization requests for patients on Highmark’s system. DME authorizations can also be submitted by fax for all patients on Highmark’s system at 1-833-619-5745 (medical outpatient). Fax forms will be available on Highmark’s Provider Resource Center beginning November 1, 2021.

For more information about the Highmark affiliation, please visit our provider resource page by clicking below.

Recent Articles

  • CAA, No Surprises, and Transparency in Coverage Legislation for 2022
    Beginning January 1, 2022, we will implement additional policies and procedures to meet regulatory guidance from the Consolidated Appropriations Act (CAA), No Surprises Act (NSA), and the Transparency in Coverage Rule (TCR). This article provides more information about how we’re addressing the legislation and a link to our Transparency Requirements FAQ.
  • Enumeration for Advanced Practice Providers (APPs)
    Beginning January 1, 2022, Advanced Practice Providers (APPs) will no longer be required to be fully credentialed with us. As we affiliate with Highmark, APPs will only be required to complete a simple online enumeration form within Highmark’s systems. In this article, you can learn more about this new enumeration process.
  • Updated Drug Therapy Guidelines and Coverage Change for Remicade and Inflectra Available Online - November 2021
    Drug therapy guidelines for Cimzia, Entyvio, Ilumya, Infliximab, and Medicare Part B Step Therapy Management have been updated, will be posted on our website by December 1 and will be effective January 1, 2022. Beginning January 1, 2022, Remicade and the biosimilar Inflectra will be co-preferred on the medical benefit for all of your Highmark BCBSWNY commercial patients, including your self-insured ASO patients.
  • Highmark Medical Policy Updates Available Online – November 2021
    Highmark’s monthly Medical Policy Update newsletter will be available online on or before November 29. These changes may impact only your patients who have moved onto Highmark’s system (beginning November 1).
  • Maintaining Participation Status in Our Network
    Highmark BCBSWNY is required by New York State, NCQA, and the Centers for Medicare and Medicaid Services (CMS) to have accurate and updated provider information and credentialing applications on file. We want to remind you that you must update and attest to your CAQH credentialling application as changes occur, or at least every 90 days. If your CAQH profile is not maintained, you may be terminated from our network and required to submit a new enrollment application. Here, you can access CAQH online.

Working with Us

Additional Resources

We want to hear from you! Have a topic request for the next Blue Bulletin? Email us

Stay in Touch! Sign up to receive emails for provider news and information